Summary: Kidney Transplant Patients

Genotypes 1 and 4

Recommended regimens listed by evidence level and alphabetically for:

Treatment-Naive and -Experienced Kidney Transplant Patients With Genotype 1 or 4 Infection, With or Without Compensated Cirrhosis

RECOMMENDED DURATION RATING

Daily fixed-dose combination of glecaprevir (300 mg)/pibrentasvir (120 mg)b

12 weeks I, Ac
IIa, Cd
Daily fixed-dose combination of ledipasvir (90 mg)/sofosbuvir (400 mg) 12 weeks I, A
a For decompensated cirrhosis, please refer to the appropriate section.
b This is a 3-tablet coformulation. Please refer to the prescribing information.
c Evidence for patients without cirrhosis
d Evidence for patients with compensated cirrhosis

 

Genotypes 2, 3, 5, and 6

Recommended and alternative regimens for:

Treatment-Naive and -Experienced Kidney Transplant Patients With Genotype 2, 3, 5, or 6 Infection, With or Without Compensated Cirrhosis

RECOMMENDED DURATION RATING
Daily fixed-dose combination of glecaprevir (300 mg)/pibrentasvir (120 mg)b 12 weeks I, Ac
IIa, Cd
ALTERNATIVE DURATION RATING
Daily daclatasvir (60 mg) plus sofosbuvir (400 mg) plus low initial dose of ribavirin (600 mg; increase as tolerated) 12 weeks II, A
a For decompensated cirrhosis, please refer to the appropriate section.
b This is a 3-tablet coformulation. Please refer to the prescribing information.
c Genotypes 2, 3, and 6
d Genotype 5
Last update: 
September 21, 2017
Top